Prime Medicine Inc., the gene-editing startup co-founded by the scientist behind Editas Medicine Inc. and Beam Therapeutics, has gone public in a $175 million IPO.
Prime Medicine Inc., the gene-editing startup co-founded by the scientist behind Editas Medicine Inc. and Beam Therapeutics, has gone public in a $175 million IPO.
About Our Site:
The primary purpose of the site is to provide Real Estate & Mortgage information as it relates to today’s business environment. It can also be used to answer related question you might have about buying, selling, or financing real estate.